Table 1.
IBD all population | Treatment group | Placebo group | Adj.P | |
---|---|---|---|---|
Male, n, % | 36, 73.46 | 15, 71.4 | 21, 75 | 1 |
Median Age, years | 51 (19‐73) | 51(19‐69) | 50(25‐73) | 1 |
Median BMI | 24.12(16.04‐30.02) | 23.84 | 24.21 | 1 |
Type of disease, n, % | CD, 19, 38.77 | 7 | 12 | 1 |
Montreal classification UC, n, % | ||||
E1 | 2, 6.6 | 1 | 1 | 1 |
E2 | 13, 43.3 | 6 | 7 | |
E3 | 15, 50 | 7 | 8 | |
CD behavior, n, % | ||||
B1 | 16, 84.2 | 4 | 12 | .08 |
B2 | 3, 15.7 | 3 | — | |
B3 | 0 | — | — | |
Location, n, % | ||||
L1 | 5, 26.3 | 3 | 2 | .48 |
L2 | 5, 26.3 | — | 5 | |
L3 | 9, 47.3 | 4 | 5 | |
Endoscopic score | ||||
Mayo score, n, % | ||||
0 | 14, 46.6 | 7 | 7 | 1 |
1 | 8, 26.6 | 4 | 4 | |
2 | 5, 16.6 | 3 | 2 | |
3 | 3, 10 | — | 3 | |
SES‐CD, n, % | ||||
0‐2 | 9, 47.36 | 3 | 6 | 1 |
3‐6 | 7, 36.8 | 3 | 4 | |
7‐15 | 3, 15.7 | 1 | 2 | |
>15 | 0 | — | — | |
Previous surgery n (CD‐UC), % | 7, 31.5 | 6 (5‐1) | 1 (1‐0) | .12 |
Smokers CD, UC | 3, 2 | 2 | 3 | 1 |
Therapy | ||||
Biologics n, % | 20, 40.8 | 8 | 12 | 1 |
5‐ASA n, % | 45, 91.8 | 20 | 25 | 1 |
Probiotics(ECN) n, % | 4, 8.1 | 2 | 2 | 1 |
Steroids n, % | 7, 14 | 1 | 6 | .84 |
Immunosuppressant n, % | 6, 12.2 | 3 | 3 | 1 |
PPI | 7, 14 | 1 | 6 | .84 |
Baseline characteristics of CD (n = 19) an UC (n = 30) patients allocated on the butyrose(treatment) or placebo groups. The adj.P‐value was calculated as described on the statistical data analysis.